Sunshine Biopharma, Inc. (SBFM)
USD 2.75
(0.37%)
USD 2.75
(0.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.82 Million USD | 42.98% |
| 2022 | -26.44 Million USD | -234.94% |
| 2021 | -12.09 Million USD | 7.26% |
| 2020 | -2.6 Million USD | -177.67% |
| 2019 | -948.38 Thousand USD | 52.61% |
| 2018 | -1.94 Million USD | -114.44% |
| 2017 | -928.78 Thousand USD | 0.52% |
| 2016 | -932.37 Thousand USD | -20.15% |
| 2015 | -1.34 Million USD | 55.78% |
| 2014 | -9768.00 USD | 9.35% |
| 2013 | -555.03 Thousand USD | -173.97% |
| 2012 | -4562.00 USD | -27.05% |
| 2011 | -556.2 Thousand USD | -3.5% |
| 2010 | -537.38 Thousand USD | -3333.53% |
| 2009 | -1.2 Million USD | 39.99% |
| 2008 | -26.07 Thousand USD | -98.74% |
| 2007 | -13.12 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.21 Million USD | 32.73% |
| 2024 Q1 | -1.3 Million USD | -2.16% |
| 2023 Q3 | -534.83 Thousand USD | 28.85% |
| 2023 Q1 | -1.58 Million USD | 67.79% |
| 2023 Q2 | -751.69 Thousand USD | 52.44% |
| 2023 Q4 | -855.13 Thousand USD | -59.89% |
| 2023 FY | - USD | 42.98% |
| 2022 Q4 | -4.9 Million USD | -236.91% |
| 2022 Q2 | -547.46 Thousand USD | 55.13% |
| 2022 FY | - USD | -234.94% |
| 2022 Q1 | -1.22 Million USD | -341.41% |
| 2022 Q3 | -1.45 Million USD | -166.0% |
| 2021 Q3 | -493.07 Thousand USD | -27.94% |
| 2021 Q1 | -1.27 Million USD | 46.92% |
| 2021 Q4 | -276.44 Thousand USD | 43.93% |
| 2021 Q2 | -385.4 Thousand USD | 69.71% |
| 2021 FY | - USD | 7.26% |
| 2020 FY | - USD | -177.67% |
| 2020 Q4 | -2.39 Million USD | -3659.6% |
| 2020 Q2 | -621.07 Thousand USD | -630.94% |
| 2020 Q3 | -63.76 Thousand USD | 89.73% |
| 2020 Q1 | -84.96 Thousand USD | 77.41% |
| 2019 FY | - USD | 52.61% |
| 2019 Q1 | -126.63 Thousand USD | 61.59% |
| 2019 Q2 | -105.56 Thousand USD | 16.64% |
| 2019 Q3 | -319.88 Thousand USD | -203.01% |
| 2019 Q4 | -376.06 Thousand USD | -17.56% |
| 2018 FY | - USD | -114.44% |
| 2018 Q4 | -329.65 Thousand USD | 60.97% |
| 2018 Q3 | -844.66 Thousand USD | -37.06% |
| 2018 Q2 | -616.28 Thousand USD | -210.79% |
| 2018 Q1 | -198.29 Thousand USD | 16.45% |
| 2017 Q4 | -237.33 Thousand USD | -115.82% |
| 2017 Q3 | -109.97 Thousand USD | 76.69% |
| 2017 Q2 | -471.71 Thousand USD | -334.9% |
| 2017 Q1 | -108.46 Thousand USD | 66.16% |
| 2017 FY | - USD | 0.52% |
| 2016 Q4 | -320.53 Thousand USD | -217.19% |
| 2016 FY | - USD | -20.15% |
| 2016 Q3 | -101.05 Thousand USD | 77.86% |
| 2016 Q2 | -456.35 Thousand USD | -738.29% |
| 2016 Q1 | -54.43 Thousand USD | 68.76% |
| 2015 Q2 | -368.15 Thousand USD | -194.94% |
| 2015 Q3 | -113.05 Thousand USD | 69.29% |
| 2015 Q4 | -174.24 Thousand USD | -54.12% |
| 2015 FY | - USD | 55.78% |
| 2015 Q1 | -124.82 Thousand USD | 59.25% |
| 2014 Q3 | -277.42 Thousand USD | 63.76% |
| 2014 FY | - USD | 9.35% |
| 2014 Q2 | -765.51 Thousand USD | -88.61% |
| 2014 Q4 | -306.3 Thousand USD | -10.41% |
| 2014 Q1 | -405.87 Thousand USD | 40.78% |
| 2013 Q2 | -152.59 Thousand USD | 83.47% |
| 2013 Q1 | -922.89 Thousand USD | -390.23% |
| 2013 Q4 | -685.41 Thousand USD | -285.75% |
| 2013 FY | - USD | -173.97% |
| 2013 Q3 | -177.68 Thousand USD | -16.44% |
| 2012 Q3 | -376.4 Thousand USD | -266.54% |
| 2012 Q2 | -102.69 Thousand USD | -161.14% |
| 2012 Q4 | -188.25 Thousand USD | 49.99% |
| 2012 Q1 | -39.32 Thousand USD | 89.43% |
| 2012 FY | - USD | -27.05% |
| 2011 Q4 | -372.05 Thousand USD | -219.52% |
| 2011 Q3 | -116.44 Thousand USD | -606.13% |
| 2011 Q1 | -49.21 Thousand USD | 89.68% |
| 2011 FY | - USD | -3.5% |
| 2011 Q2 | -16.49 Thousand USD | 66.49% |
| 2010 Q2 | -1.58 Million USD | -10444.99% |
| 2010 Q4 | -476.94 Thousand USD | -131.54% |
| 2010 FY | - USD | -3333.53% |
| 2010 Q3 | 1.51 Million USD | 195.23% |
| 2010 Q1 | 15.35 Thousand USD | 0.0% |
| 2009 FY | - USD | 39.99% |
| 2009 Q3 | 1.06 Million USD | 20695.63% |
| 2009 Q2 | -5191.00 USD | -110.16% |
| 2009 Q1 | -2470.00 USD | 26.33% |
| 2008 Q3 | -4638.00 USD | -9.31% |
| 2008 Q4 | -3353.00 USD | 27.71% |
| 2008 FY | - USD | -98.74% |
| 2008 Q1 | -10.78 Thousand USD | -376.03% |
| 2008 Q2 | -4243.00 USD | 60.65% |
| 2007 Q4 | -2265.00 USD | 74.23% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | -8788.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | 62.916% |
| Harrow Health, Inc. | 9.72 Million USD | 139.334% |
| Dynavax Technologies Corporation | 9.66 Million USD | 139.566% |
| Biofrontera Inc. | -18.45 Million USD | 79.275% |
| Cronos Group Inc. | -72.14 Million USD | 94.699% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 15.482% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 99.586% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 89.401% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 114.56% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -438.006% |
| Radius Health, Inc. | 38.31 Million USD | 109.983% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -18.953% |
| DURECT Corporation | -24.68 Million USD | 84.506% |
| ProPhase Labs, Inc. | -14.82 Million USD | 74.206% |
| Safety Shot Inc | -12.18 Million USD | 68.614% |
| Phibro Animal Health Corporation | 84.6 Million USD | 104.52% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -62.671% |
| Alvotech | -484.86 Million USD | 99.211% |
| Assertio Holdings, Inc. | -222.44 Million USD | 98.281% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 103.892% |
| Rockwell Medical, Inc. | -4.69 Million USD | 18.525% |
| Procaps Group S.A. | 104.02 Million USD | 103.676% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 97.592% |
| SCYNEXIS, Inc. | 73.47 Million USD | 105.205% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -277.907% |
| Viatris Inc. | 3.51 Billion USD | 100.109% |
| OptiNose, Inc. | -15.55 Million USD | 75.41% |
| SIGA Technologies, Inc. | 84.15 Million USD | 104.544% |
| Tilray Brands, Inc. | -72.84 Million USD | 94.75% |
| PetIQ, Inc. | 81.48 Million USD | 104.693% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -0.0% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 100.919% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 2.497% |
| Alimera Sciences, Inc. | 7.27 Million USD | 152.562% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 101.24% |
| Silver Spike Investment Corp. | 7.34 Million USD | 152.103% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 4.166% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 110.614% |
| Journey Medical Corporation | 1.92 Million USD | 299.085% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 9.199% |
| Alpha Teknova, Inc. | -25.53 Million USD | 85.025% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 77.241% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 570.987% |
| PainReform Ltd. | -9.56 Million USD | 60.033% |
| Cosmos Health Inc. | -17.06 Million USD | 77.585% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 97.435% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 54.477% |
| Embecta Corp. | 245.4 Million USD | 101.558% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -5.716% |
| Talphera, Inc. | -9.84 Million USD | 61.142% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 102.348% |
| Incannex Healthcare Limited | -18.5 Million USD | 79.332% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 80.907% |
| Shineco, Inc. | -26.55 Million USD | 85.598% |
| Procaps Group, S.A. | 104.02 Million USD | 103.676% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 103.498% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 423.555% |
| Lantheus Holdings, Inc. | 491 Million USD | 100.779% |
| Alvotech | -484.86 Million USD | 99.211% |
| Hempacco Co., Inc. | -12.77 Million USD | 70.059% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 104.935% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 97.452% |
| Kamada Ltd. | 21.53 Million USD | 117.76% |
| Indivior PLC | 66 Million USD | 105.795% |
| Evoke Pharma, Inc. | -7.29 Million USD | 47.555% |
| Flora Growth Corp. | -45.87 Million USD | 91.662% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 80.907% |
| Evolus, Inc. | -41.81 Million USD | 90.853% |
| HUTCHMED (China) Limited | 25.52 Million USD | 114.981% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 101.584% |
| Akanda Corp. | -27.73 Million USD | 86.211% |